Short Interest in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Rises By 94.5%

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 7,780,000 shares, an increase of 94.5% from the December 31st total of 4,000,000 shares. Based on an average daily volume of 100,730,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 4.2% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research note on Saturday. They issued a “hold” rating on the stock.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. 82.26% of the stock is owned by institutional investors.

Tonix Pharmaceuticals Trading Down 6.5 %

NASDAQ:TNXP traded down $0.03 during mid-day trading on Wednesday, hitting $0.43. The company had a trading volume of 144,079,347 shares, compared to its average volume of 108,265,703. The firm has a market cap of $80.36 million, a P/E ratio of -0.01 and a beta of 2.02. Tonix Pharmaceuticals has a fifty-two week low of $0.12 and a fifty-two week high of $12.48. The business’s fifty day moving average is $0.29 and its two-hundred day moving average is $0.28. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. As a group, research analysts expect that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.